WMT

124.39

-0.26%↓

COST

972.11

-1.3%↓

TGT

118.98

+0.5%↑

67.09

-1.44%↓

CASY

737.41

+0.86%↑

WMT

124.39

-0.26%↓

COST

972.11

-1.3%↓

TGT

118.98

+0.5%↑

67.09

-1.44%↓

CASY

737.41

+0.86%↑

WMT

124.39

-0.26%↓

COST

972.11

-1.3%↓

TGT

118.98

+0.5%↑

67.09

-1.44%↓

CASY

737.41

+0.86%↑

WMT

124.39

-0.26%↓

COST

972.11

-1.3%↓

TGT

118.98

+0.5%↑

67.09

-1.44%↓

CASY

737.41

+0.86%↑

WMT

124.39

-0.26%↓

COST

972.11

-1.3%↓

TGT

118.98

+0.5%↑

67.09

-1.44%↓

CASY

737.41

+0.86%↑

Home・Akciju saraksts・Lifecore Biomedical Inc

Lifecore Biomedical Inc

Atvērts

SektorsPatēriņa aizsardzības

5.24 8.26

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

4.83

Max

5.15

Galvenie mērījumi
By Trading Economics
Ienākumi	-7.9M -10M
Pārdošana	-5.3M 31M
Peļņas marža	-32.116
Darbinieki	400

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+36.84% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 10. jūn.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-118M 123M
Iepriekšējā atvēršanas cena	-3.02
Iepriekšējā slēgšanas cena	5.24

Ziņu noskaņojums

By Acuity

72%

28%

119 / 131 Rangs Consumer defensive

Lifecore Biomedical Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 13. apr. 23:25 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

2026. g. 13. apr. 22:45 UTC

Galvenie ziņu notikumi

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

2026. g. 13. apr. 18:03 UTC

Peļņas

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

2026. g. 13. apr. 23:58 UTC

Peļņas

Review & Preview: Earnings Time -- Barrons.com

2026. g. 13. apr. 23:49 UTC

Tirgus saruna

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

2026. g. 13. apr. 23:33 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Edges Higher Amid Dollar Weakness -- Market Talk

2026. g. 13. apr. 23:20 UTC

Tirgus saruna

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

2026. g. 13. apr. 23:01 UTC

Peļņas

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

2026. g. 13. apr. 22:21 UTC

Iegādes, apvienošanās, pārņemšana

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

2026. g. 13. apr. 21:53 UTC

Peļņas

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

2026. g. 13. apr. 21:26 UTC

Galvenie ziņu notikumi

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

2026. g. 13. apr. 21:23 UTC

Peļņas

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

2026. g. 13. apr. 21:16 UTC

Peļņas

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 13. apr. 20:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

2026. g. 13. apr. 20:34 UTC

Peļņas

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

2026. g. 13. apr. 19:59 UTC

Tirgus saruna

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

2026. g. 13. apr. 19:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

2026. g. 13. apr. 19:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Correction to Precious Metals Market Talk on April 9

2026. g. 13. apr. 19:14 UTC

Tirgus saruna

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

2026. g. 13. apr. 18:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

2026. g. 13. apr. 18:43 UTC

Tirgus saruna

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Salīdzinājums

Cenas izmaiņa

Lifecore Biomedical Inc Prognoze

Cenas mērķis

By TipRanks

36.84% augšup

Prognoze 12 mēnešiem

Vidējais 6.5 USD 36.84%

Augstākais 9 USD

Zemākais 5 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Lifecore Biomedical Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

119 / 131 Rangs Patēriņa aizsardzības

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Lifecore Biomedical Inc

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States. The company engages in the manufacturing of injectable grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.